AstraZeneca Seroquel XR Generic Delay Antitrust Complaint

October 1, 2019

A number of antitrust class actions in recent years have centered on covert agreements between a company with a popular and lucrative drug and one or more other companies who may wish to put out a generic version. In this antitrust class action, the complaint claims that AstraZeneca companies entered into agreements with Handa Pharmaceuticals, LLC and Par Pharmaceutical, Inc. to delay the entry of generic versions of AstraZeneca’s Seroquel XR into the market.

Case Event File: AstraZeneca Seroquel XR Generic Delay Antitrust Complaint

Related to: AstraZeneca Seroquel XR Generic Delay Antitrust Class Action